Advanced Search
Submit one or more of the following items, and they will be searched along with your query in the search box above.
Any submit button will submit all of the items you have changed.

+ Publication-Date Published in the last:

30 days
60 days
90 days
6 months
12 months
this year
2 years
3 years
5 years
10 years

Or published in the following date range:
From (yyyy/mm/dd - month and day are optional) to ('to' is optional)
+ Full Text
Retrieve articles with hyperlinks to:
full text (either free or subscription)
free full text
subscription full text
no full text link
+ Sort-Order
Sort the retrieved articles by:
relevance
publication date
+ Language And with languages:

+ Species
And for:
Humans
Animals
+ Gender
And for:
Male
Female
+ Age And for these age groups:

Newborn: birth to 1 month
Infant: 1 to 23 months
Preschool child: 2 to 5 years
Child: 6 to 12 years
Adolescent: 13 to 18 years
Adult: 19 to 44 years
Middle aged: 45 to 64 years
Aged: 65+ years
80 and over: 80+ years

+ Title
And for this query matching the titles:
+ Transliterated-Title
And for this query matching the title in original language:
+ Abstract
And for this query matching the abstratcs:
+ Major-Mesh
And for this query matching the MeSH-Major terms:
+ Mesh
And for this query matching any MeSH terms:
+ Journal
And for one or more of these journal abbreviated names:
OR OR
(see title abbreviations)+ Volume
And with journal volume number:
+ Issue
And with journal issue number:
+ Page
And with page number:
+ ISSN
And with ISSN:
+ Publication-Place
And with journal's country of publication:
+ Author

+ Affiliation
And with affiliation to:
+ Has-Abstract
Find MEDLINE records with the abstract status:
has abstract
does not have abstract
include both record types
include both record types but rank higher the records having abstract (the default BML behavior) + PMID
Show me only articles for these PMIDs (PubMed IDs):
+ Semantic-Type And with semantic types:

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

We performed a systematic comparison between RISH and PCR for EBV detection, in a group of childhood B-cell Non-Hodgkin lymphomas (NHL), aiming to validate PCR as a first, rapid method for the diagnosis of EBV-associated B-cell NHL.

METHODS: EBV infection was investigated in formalin fixed paraffin-embedded tumor samples of 41 children with B-cell NHL, including 35 Burkitt's lymphoma (BL), from Rio de Janeiro, Brazil, by in situ hybridization of EBV-encoded small RNA (EBER-RISH) and PCR assays based on EBNA2 amplification.

[Email]Email this result itemEmail the results to the following email address: [X] Close

[Email]Email this result itemEmail the results to the following email address: [X] Close

(PMID = 17958830.001).

[ISSN] 1525-1470

[Journal-full-title] Pediatric dermatology

[ISO-abbreviation] Pediatr Dermatol

[Language] eng

[Publication-type] Case Reports; Letter

[Publication-country] United States

3. Kawamura M, Kaku H, Taketani T, Taki T, Shimada A, Hayashi Y: Mutations of GATA1, FLT3, MLL-partial tandem duplication, NRAS, and RUNX1 genes are not found in a 7-year-old Down syndrome patient with acute myeloid leukemia (FAB-M2) having a good prognosis.Cancer Genet Cytogenet; 2008 Jan 1;180(1):74-8[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Mutations of GATA1, FLT3, MLL-partial tandem duplication, NRAS, and RUNX1 genes are not found in a 7-year-old Down syndrome patient with acute myeloid leukemia (FAB-M2) having a good prognosis.

The prognosis of leukemia developed in Down syndrome (DS) patients has improved markedly.

Most DS leukemia occurs before 3 years of age and is classified as acute megakaryocytic leukemia (AMKL).

In contrast, it has been shown that occurrence of DS acute myeloid leukemia (DS-AML) after 3 years of age may indicate a higher risk for a poor prognosis, but its frequency is very low.

We here describe the case of a 7-year-old DS boy with AML-M2, who had no history of transient abnormal myelopoiesis or any clinical poor prognostic factors, such as high white blood cell counts or extramedullary infiltration.

Accumulation of more data on older pediatric DS-AML patients is needed.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] The role of hematopoietic stem cell transplantation with relapsed or primary refractory childhood B-cell non-Hodgkin lymphoma and mature B-cell leukemia: a retrospective analysis of enrolled cases in Japan.

BACKGROUND: There have been excellent treatment results for children with B-cell non-Hodgkin lymphoma (B-NHL) and mature B-cell leukemia (B-ALL) in the last few decades.

Among 18 patients who had a chemotherapy-sensitive disease, 4 of 5 patients who underwent hematopoietic stem cell transplantation (HSCT) during remission survived without progression, while 3 of 12 patients who did not receive HSCT were alive without disease progression.

The present study was performed to determine (a) the degree of changes in immunophenotype and their consequences on the monitoring of minimal residual disease (MRD) in childhood AML and (b) whether certain clusters of changes in antigen expression patterns exist between diagnosis and relapse.

METHODS: Bone marrow specimens of 48 children enrolled in the German AML-BFM-93/98 (Acute Myeloid Leukemia-Berlin-Frankfurt-Munster) studies were analyzed immunologically, morphologically, and genetically at diagnosis and at first relapse.

We did not observe significant changes for lineage specific markers, with comparable occurrences of loss or gain of myeloid and lymphoid antigens in the sample pairs.

The antibody panels used for MRD monitoring in childhood AML should therefore not be restricted to the immunophenotype detected at presentation but should include in particular markers of lineage immaturity.

The clinical observation of a shift toward a more immature phenotype of the myeloblasts is consistent with the model of a clonal evolution of a leukemic stem cell.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

BACKGROUND: Acutelymphoblasticleukemia is a malignant disease of the bone marrow in which early lymphoid precursors proliferate and replace normal marrow hematopoietic cells, resulting in a marked decrease in the production of normal blood cells.

CONCLUSION: In contrast to testicular relapse, ovarian relapses in acutelymphoblasticleukemia are rarely reported.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Fusion proteins composed of the histone methyltransferase mixed-lineage leukemia (MLL) and a variety of unrelated fusion partners are highly leukemogenic.

Despite their prevalence, particularly in pediatric acute leukemia, many molecular details of their transforming mechanism are unknown.

Here, we provide mechanistic insight into the function of MLL fusions, demonstrating that they capture a transcriptional elongation complex that has been previously found associated with the eleven-nineteen leukemia protein (ENL).

[Other-IDs] NLM/ PMC2774266

8. Chowdhury T, Brady HJ: Insights from clinical studies into the role of the MLL gene in infant and childhood leukemia.Blood Cells Mol Dis; 2008 Mar-Apr;40(2):192-9[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Insights from clinical studies into the role of the MLL gene in infant and childhoodleukemia.

Translocations involving the Mixed Lineage Leukemia (MLL) gene at 11q23 are found in both acutelymphoblasticleukemia (ALL) and acute myeloblastic leukemia (AML), but have different prognostic implications depending on the phenotype of the leukemia in de novo pediatric cases.

This review considers recent advances in our understanding of the role of MLL gene rearrangements in pediatric clinical practice.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Pediatric acutelymphoblasticleukemia (ALL) is a heterogeneous disease consisting of distinct clinical and biological subtypes that are characterized by specific chromosomal abnormalities or gene mutations.

We recently identified a poor prognostic subgroup of pediatric BCR-ABL1-negative ALL patients characterized by deletion of IKZF1 (encoding the lymphoid transcription factor IKAROS) and a gene expression signature similar to BCR-ABL1-positive ALL, raising the possibility of activated tyrosine kinase signaling within this leukemia subtype.

11. Cowan SA: Denmark decides not to introduce hepatitis B into the childhood vaccination programme.Euro Surveill; 2005;10(11):E051103.3[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Denmark decides not to introduce hepatitis B into the childhood vaccination programme.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Acute leukemia, the most common form of cancer in children, accounts for approximately 30% of all childhood malignancies, with acutelymphoblasticleukemia being five times more frequent than acute myeloid leukemia.

Lineage switch is the term that has been used to describe the phenomenon of acute leukemias that meet the standard French-American-British system criteria for a particular lineage (either lymphoid or myeloid) upon initial diagnosis, but meet the criteria for the opposite lineage at relapse.

Many reports have documented conversions of acutelymphoblasticleukemia to acute myeloid leukemia.

Here, we report the case of a 4-year-old child with acute myeloid leukemia, which upon relapse switched to acutelymphoblasticleukemia.

[Email]Email this result itemEmail the results to the following email address: [X] Close

(PMID = 19946525.001).

[ISSN] 1757-1626

[Journal-full-title] Cases journal

[ISO-abbreviation] Cases J

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

[Other-IDs] NLM/ PMC2783110

13. Xie XT, Jiang SY, Li BS, Yang LL: [Relationship between the expression of the genes encoding the key enzymes for cytarabine metabolism and the pharmacokinetics of cytarabine in the treatment of childhood acute leukemia with high-dose cytarabine].Zhonghua Er Ke Za Zhi; 2008 Apr;46(4):276-80[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Relationship between the expression of the genes encoding the key enzymes for cytarabine metabolism and the pharmacokinetics of cytarabine in the treatment of childhoodacute leukemia with high-dose cytarabine].

This study aimed to evaluate the pharmacokinetics of HD-AraC for childhood hematological malignancies, and the relationship between the expression of the genes coding the key enzymes for Ara-C metabolism with the outcome of the patients.

METHODS: The drug levels of Ara-C in plasma and cerebrospinal fluid were detected with HPLC while HD-AraC was used, the expression of deoxycytidine kinase (dCK) and cytidine deaminase (CDA) mRNA in human leukemia cell lines and the bone marrow cells were investigated in 48 cases of childhood hematological malignancies with RT-PCR methods, and the relationship between the expression of these enzymes mRNA and the outcome of the patients was analyzed. RESULTS:.

(1) When HD-AraC was used, the plasma levels of Ara-C and Ara-U could be respectively about 50 times and 25 times higher than those obtained when the patients were treated with regular dose of Ara-C treatment, and the level of Ara-C in cerebrospinal fluid could reach about 10% of plasma level of Ara-C. (2) There were significantly different expressions of dCK mRNA in different childhoodacute leukemia (AL) patients, which were markedly related to the chemotherapy results.

There were no significant differences in expressions of dCK in T-ALL and B lineage ALL. (3) In vitro study found that the expressions of dCK and CDA mRNA did not change in leukemia cell lines incubated at different doses and times of Ara-C.

CONCLUSIONS: HD-AraC was a very effective protocol for childhood hematological malignancies for it could significantly elevate the plasma and cerebrospinal fluid drug levels.

Good long-term outcomes of the childhood T-ALL could be achieved as the B lineage ALL had been treated with HD-AraC regimen.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Clinical characteristics and outcome of children with biphenotypic acute leukemia.

BACKGROUND: Knowledge concerning the clinical and biological presentation, as well as the outcome of treatment, of biphenotypic acute leukemia in children is limited.

DESIGN AND METHODS: This retrospective review analyzes the clinical features and outcome of children with biphenotypic acute leukemia diagnosed and treated over an 8-year period.

According to the EGIL scoring system 24 (3.7%) of 633 patients with acute leukemia were classified as having biphenotypic acute leukemia.

The diagnostic work-up and results were reviewed specifically for this study in the light of the newly published WHO criteria for the diagnosis of leukemia of ambiguous lineage.

Based on these criteria, 11 (1.7%) patients were categorized according to the new nomenclature as having mixed phenotype acute leukemia.

The majority of the patients (58.3%) had a B-lymphoid/myeloid phenotype, followed by the T-lymphoid/myeloid phenotype.

Patients received therapy based on a treatment regimen for acutelymphocyticleukemia regimen, which included myeloid-effective agents.

The survival of those patients who underwent hematopoietic stem cell transplantation in first complete remission was not different from that of the patients who were treated with chemotherapy alone (overall survival: 70.1% versus 81.1%, respectively, p=0.39; event-free survival: 70.1% versus 76.2%, respectively, p=0.75).

The outcome of the 11 patients who were retrospectively classified as having mixed phenotype acute leukemia according to the new WHO criteria was excellent, with no relapses or deaths occurring among these patients.

CONCLUSIONS: An acutelymphocyticleukemia type of induction therapy, using agents that are active against lymphoid and myeloid leukemias, appears to be more effective in achieving and maintaining complete remissions regardless of whether the patients are classified according to EGIL criteria or the new WHO criteria.

Hematopoietic stem cell transplantation may not be necessary for all patients in first complete remission.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Effect of allopurinol versus urate oxidase on methotrexate pharmacokinetics in children with newly diagnosed acutelymphoblasticleukemia.

BACKGROUND: Allopurinol and urate oxidase are both effective in preventing or treating hyperuricemia during remission induction therapy for lymphoid malignancies, but to the authors' knowledge, their effects on concomitant anticancer drug therapy have not been compared.

Hence, during remission induction therapy for lymphoid malignancies, the authors concluded that renally excreted drugs should be monitored closely, especially in patients who are receiving allopurinol.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

INTRODUCTION: Infant acutelymphoblasticleukemia (ALL) is considered a high-risk entity.

By morphology, infant ALL is classified as a lymphoid lineage leukemia; however, its physiologic behavior has brought many to consider it a pathologic hybrid between lymphoid leukemia and myeloid leukemias.

The role of hematopoietic stem cell transplantation and graft-versus-leukemia effect in these patients has not been well studied.

CONCLUSION: Traditionally, graft-versus-leukemia effect was thought to contribute therapeutically little to the treatment of ALL by hematopoietic stem cell transplantation (HSCT).

The effects of graft-versus-leukemia immunologic phenomenon in our patient with infant acutelymphoblasticleukemia underscore the potential that infant ALL may not be entirely the same biologic entity as standard pediatric ALL and may be more responsive than understood earlier.

Therapeutic response and appearance of GVHD after the withdrawal of immunosuppression in this patient provides evidence that graft-versus-leukemia effect may play a role in disease control in infant ALL after HSCT.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Polymorphisms of methylenetetrahydrofolate reductase (MTHFR) and susceptibility to pediatric acutelymphoblasticleukemia in a German study population.

Two common polymorphisms (677C>T and 1298A>C) in the gene coding for MTHFR have been shown to reduce MTHFR enzyme activity and were associated with the susceptibility to different disorders, including vascular disease, neural tube defects and lymphoid malignancies.

Studies on the role of these polymorphisms in the susceptibility to acutelymphoblasticleukemia (ALL) led to discrepant results.

METHODS: We retrospectively evaluated the association of the MTHFR 677C>T and 1298A>C polymorphisms with pediatric ALL by genotyping a study sample of 443 ALL patients consecutively enrolled onto the German multicenter trial ALL-BFM 2000 and 379 healthy controls.

We calculated odds ratios of MTHFR genotypes based on the MTHFR 677C>T and 1298A>C polymorphisms to examine if one or both of these polymorphisms are associated with pediatric ALL.

CONCLUSION: Our findings suggest that the MTHFR 677C>T and 1298A>C gene variants do not have a major influence on the susceptibility to pediatric ALL in the German population.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

This report is the first to describe the successful treatment of a 14-year-old boy with aggressive recurrent, CD20-positive, B-cell large cell non-Hodgkin's lymphoma.

Rituximab and CHOP in addition to chemotherapy may be an alternative treatment for aggressive recurrent, pediatric CD20-positive B-cell large cell non-Hodgkin's lymphoma if highly intensive chemotherapy and stem cell transplantation are not available.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Clinical features and prognostic implications of TCF3-PBX1 and ETV6-RUNX1 in adult acutelymphoblasticleukemia.

BACKGROUND: The t(9;22) and t(4;11) chromosomal translocations, which generate the BCR-ABL and MLL-AF4 fusion genes, define high-risk subtypes of acutelymphoblasticleukemia in adults.

However, the prognostic impact of other rarer fusion genes is less well established in adult acutelymphoblasticleukemia than in the childhood form.

DESIGN AND METHODS: In the context of the German Multicenter Therapy Study Group for Adult AcuteLymphoblasticLeukemia (GMALL) we used reverse transcriptase polymerase chain reaction to investigate 441 cases of BCR-ABL- and MLL-AF4-negative B-precursoracutelymphoblasticleukemia for the TCF3-PBX1 (E2A-PBX1) and ETV6-RUNX1 (TEL-AML1) fusion transcripts generated by the t(1;19)(q23;p13.3) and t(12;21)(p13;q22) translocations.

Both are well-known molecular alterations in pediatric acutelymphoblasticleukemia in which they have favorable prognostic implications.

CONCLUSIONS: In contrast to previous suggestions, adult patients with TCF3-PBX1-positive acutelymphoblasticleukemia do not appear to have a worse outcome than their negative counterparts.

Although the dic(9;20)(p11-13;q11) is a recurrent chromosomal abnormality in paediatric B-cellprecursoracutelymphoblastic leukaemia (BCP ALL), occurring in approximately 2% of the cases, its molecular genetic consequences have not been elucidated.

In the present study, high-resolution genome-wide array-based comparative genomic hybridisation (array-CGH) and fluorescence in situ hybridisation (FISH) were used to characterise the 9p and 20q breakpoints (BPs) in seven childhood BCP ALLs with dic(9;20), which was shown to be unbalanced in all of them, resulting in loss of 9p13.2-pter.

One of the ALLs, shown to have a complex dic(9;20), was further investigated by FISH, revealing a rearrangement of the haemapoietic cell kinase isoform p61 (HCK) gene at 20q11.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

We present the unusual case of a 16-year-old girl with T-cell acutelymphoblasticleukemia (ALL) with an early thymocyte immunophenotype without myeloid markers, who after 13 months of complete hematological remission relapsed as acute myelogenous leukemia (AML) with minimal differentiation and died of her disease.

Whether the AML represented a relapse with lineage switch of the original immature T-cell clone or a new secondary malignancy, could not be proven due to the absence of molecular or clonal markers.

This report suggests that a subset of CD7+ T-cell leukemias without mature T-cell antigens (CD4-, CD8-) are minimally differentiated and can relapse as AML.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Equal frequency of TEL/AML1 rearrangements in children with acutelymphoblasticleukemia with and without Down syndrome.

Constitutional trisomy 21 is the most prominent predisposing factor to childhoodleukemia, whereas the t(12;21)(p13;q22) with its molecular genetic counterpart, the TEL/AML1 fusion gene, is the most common acquired chromosomal rearrangement in childhood B-cellprecursor (BCP) acutelymphoblasticleukemia (ALL).

Accordingly, they were able to analyze 8 of 10 individuals with DS and a BCP ALL, two of whom who suffered from a TEL/AML1+ leukemia.

Based on this observation they concluded that individuals with BCP leukemia and a constitutional trisomy 21 may have similar likelihood to have a TEL/AML1 rearrangement as BCP ALL patients without this specific predisposing factor.

[Publication-country] England

30. Stefan DC, Stones D: How much does it cost to treat children with Hodgkin lymphoma in Africa?Leuk Lymphoma; 2009 Feb;50(2):196-9[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Hodgkin lymphoma (HL) is a common B-cellchildhood neoplasm and it has a higher incidence in the 0-14 year age group in developing countries compared to developed countries.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

AIM: To analyze the clinical characteristics of B-cell non-Hodgkin's lymphoma (NHL) patients and the therapeutic efficacy of French-American-British Lymphoma Malins de Burkitt 96 and the recent United Kingdom Children's Cancer Study Group B-cell NHL guidelines in the tertiary care hospital of a developing country.

METHODS: Patients aged < or =18 years registered at our hospital between January 1995 and December 2006 with histologically proved B-Cell NHL were selected for retrospective analysis.

Of these 95 had Burkitt's lymphoma, 22 diffuse large B-cell lymphoma and five had B-cell NHL not otherwise specified.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

To investigate the immunological and other clinical characteristics in TEL/AML1+ childhood B-acutelymphoblasticleukemia (B-ALL), immunophenotyping was performed with three-color flow cytometry, and the expression of TEL-AML1 fusion gene was detected with nested RT-PCR.

(2) compared with TEL-AML1- group, no significant difference was found in age, gender, white cell count and blasts count in peripheral blood of TEL-AML1+;.

It is concluded that TEL-AML1 rearrangement is a frequent molecular abnormality in childhood ALL.

These characteristics may be useful in detection of minimal residual leukemia.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title]Leukemia stem cells and human acutelymphoblasticleukemia.

Leukemia stem cells are fairly well described for acute myeloid leukemia (AML), but their existence and relevance for acutelymphoblasticleukemia (ALL) is less clear.

However, it has also been suggested that the majority of leukemic subfractions can propagate leukemia in the appropriate experimental setting, and that their hierarchical organization is less strict than in AML.

In addition, it is uncertain whether cancer stem cells arise from malignant transformation of a tissue-specific stem cell, or from committed progenitors or differentiated cells that re-acquire a stem cell-like program.

In common childhood ALL, current evidence points towards the cell of origin being a committed lymphoid progenitor.

In this review, we highlight recent findings relating to the question of leukemia stem cells in ALL.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

While the outcome for pediatric patients with lymphoproliferative disorders (LPD) or lymphoid malignancies, such as acutelymphoblasticleukemia (ALL), has improved dramatically, patients often suffer from therapeutic sequelae.

(ii) block the interaction of ALL cells with stromal cells or lymphoid growth factors secreted by the bone marrow microenvironment; or (iii) stimulate innate and adaptive immune responses.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Prognostic effect of chromosomal abnormalities in childhood B-cellprecursoracutelymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial.

BACKGROUND: Chromosomal abnormalities in childhoodacutelymphoblastic leukaemia are well established disease markers and indicators of outcomes.

METHODS: We analysed cytogenetic data from 1725 children with B-cellprecursoracutelymphoblastic leukaemia who were included in the UK Medical Research Council ALL97/99 study and followed up for a median time of 8.2 years.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Age-related increase in the frequency of CD4(+) T cells that produce interferon-gamma in response to staphylococcal enterotoxin B during childhood.

Immune maturation is complex, however, and the interval during which changes occur during childhood has not been identified.

METHODS: To assess age-related differences in the CD4(+) T cell responses, we evaluated the frequency of CD4(+) T cells that produced interferon (IFN) gamma in response to staphylococcal enterotoxin B (SEB) stimulation in 382 healthy infants and children (2 months to 11 years of age) and 66 adults.

Observed differences in CD45RO(+)CD4(+) T cell function indicate that CD4(+) T cells with the same phenotypes do not possess equivalent functional capabilities.

45. Kouros CD, Cummings EM, Davies PT: Early trajectories of interparental conflict and externalizing problems as predictors of social competence in preadolescence.Dev Psychopathol; 2010 Aug;22(3):527-37[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Consistent with developmental cascade notions, the present study investigated (a) associations between trajectories of interparental conflict and early externalizing problems during childhood and (b) early trajectories of externalizing problems as a pathway by which interparental conflict impacts children's social competence in preadolescence.

Results from parallel process models indicated that changes in interparental conflict were positively associated with changes in externalizing problems during childhood.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Preleukemic TEL-AML1-positive clones at cell level of 10(-3) to 10(-4) do not persist into adulthood.

The TEL-AML1 translocation, t(12;21)(p13;q22), is one of the most frequent genetic aberrations in childhood B-cellprecursoracutelymphoblasticleukemia (ALL), where it occurs in 25% of all cases.

Evidence suggests that the TEL-AML1 translocation occurs in utero in 1% of all newborn children at cell levels of 10 to 10.

The observed prevalence of TEL-AML1-positive cells in healthy adults is of the same order of magnitude as the prevalence reported in healthy newborns, but the observed cell level of 10 to 10 is much lower.

These data indicates that prenatal TEL-AML1 subclones does not persist throughout adult life at cell levels of 10 to 10.

The findings are compatible with the risk of t(12;21)(p13;q22) ALL correlating with the total number of TEL-AML1-positive cells in peripheral blood in both childhood and adulthood.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

OBJECTIVE: To probe into the occurrence rates of the effective antigen combinations which were used to detect the minimal residual disease (MRD) by flow cytometry in childhood B-lineage acutelymphoblasticleukemia (B-ALL), as well as the relationship between clinical-biologic factors and different combinations.

(1) Totally 327 cases of childhood B-ALL were screened for antibody combinations of interest and 88.4 percent of them (289 cases) were identified with effective antibody combinations. (2) The occurrence frequencies of antigen combinations were different.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

B cell-activating factor belonging to the tumor necrosis factor superfamily (BAFF) is a crucial factor for B cell development and is involved in the survival of malignant B cells, but its effect on B cell precursors (BCPs) remains unclear.

Leukemias are composed of a hierarchy of cells, only a fraction of which have stem cell-like properties and are capable of self-renewal.

This provides an opportunity to assess changes in immunophenotype, gene expression, and epigenetic programs during the transition from a hematopoietic cell with minimal inherent self-renewal capability to cells capable of leukemic self-renewal.

[Publication-country] United States

[Other-IDs] NLM/ PMC2927045

55. Volbrecht MM, Goldsmith HH: Early temperamental and family predictors of shyness and anxiety.Dev Psychol; 2010 Sep;46(5):1192-205[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The B203.13 monoclonal antibody was developed by immunizing mice with the B/monocyte biphenotypic cell line B1b.

We tested this antibody as a marker of childhood B-acutelymphoblasticleukemia (B-ALL).

The CD10(+)/B203.13(+) phenotype was specific to B-ALL, since CD10(+)/CD20(+) cells from common acutelymphoblasticleukemia (c-ALL) did not express B203.13.

We concluded that the use of B203.13 in association with CD10 and CD20 provides meaningful information for distinguishing normal residual B-cells from leukemic B-lymphoblasts and that recurrence of a CD10(+)/B203.13(+) phenotype after transplantation may be a very early relapse indicator of early B-acutelymphoblasticleukemia.

Wilms' tumor gene 1 (WT1) is overexpressed in the majority (70-90%) of acute leukemias and has been identified as an independent adverse prognostic factor, a convenient minimal residual disease (MRD) marker and potential therapeutic target in acute leukemia.

Using a real-time quantitative PCR designed according to Europe Against Cancer Program recommendations, we evaluated WT1 expression in 125 consecutively enrolled patients with childhood ALL (106 BCP-ALL, 19 T-ALL) and compared it with physiologic WT1 expression in normal and regenerating bone marrow (BM).

In childhood B-cellprecursor (BCP)-ALL, we detected a wide range of WT1 levels (5 logs) with a median WT1 expression close to that of normal BM.

WT1 expression in childhood T-ALL was significantly higher than in BCP-ALL (P<0.001).

In summary, our study suggests that WT1 expression in childhood ALL is very variable and much lower than in AML or adult ALL.

WT1, thus, will not be a useful marker for MRD detection in childhood ALL, however, it does represent a potential independent risk factor in childhood ALL.

Interestingly, a proportion of childhood ALL patients express WT1 at levels below the normal physiological BM WT1 expression, and this reduced WT1 expression appears to be associated with a higher risk of relapse.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

This study was aimed to investigate the value of CD58 in evaluation of early therapeutic effect on childhood B-ALL.

The expression features of CD58 in 135 cases of childhood B-ALL were analyzed by four-color flow cytometry; MRD detection protocol for B-ALL using CD58/CD10/CD34/CD19 combination was established; the correlation between the expression features of CD58 and MRD detection was analyzed for the early therapeutic response in childhood B-ALL.

The CD58 over expression may be considered as a marker of a favorable prognosis in childhood B-ALL.

[Email]Email this result itemEmail the results to the following email address: [X] Close

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

OBJECTIVE: To determine the prognostic value of preB immunophenotype and its variants on early treatment response among of acute pediatric lymphoblast leukemia.

PATIENTS AND METHODS: A case-control study nested in a cohort was carried out with male and female patients 15 years and younger with recently diagnosed pre-B lymphoblast leukemia.

A panel of B, T, monoclonal antibodies of the myelo-monocytic and megakaryocytic cell type was used.

CONCLUSIONS: We need to pay special emphasis on early treatment response in children with lymphoblast leukemia as our study did not corroborate the common finding that clinical factors and immune phenotype can be predictive factors.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Deletion of IKZF1 and prognosis in acutelymphoblasticleukemia.

BACKGROUND: Despite best current therapy, up to 20% of pediatric patients with acutelymphoblasticleukemia (ALL) have a relapse.

METHODS: We studied a cohort of 221 children with high-risk B-cell-progenitor ALL with the use of single-nucleotide-polymorphism microarrays, transcriptional profiling, and resequencing of samples obtained at diagnosis.

A copy-number abnormality was identified as a predictor of poor outcome, and it was then tested in an independent validation cohort of 258 patients with B-cell-progenitor ALL.

RESULTS: More than 50 recurring copy-number abnormalities were identified, most commonly involving genes that encode regulators of B-cell development (in 66.8% of patients in the original cohort); PAX5 was involved in 31.7% and IKZF1 in 28.6% of patients.

This predictor was strongly associated with alteration of IKZF1, a gene that encodes the lymphoid transcription factor IKAROS.

The gene-expression signature of the group of patients with a poor outcome revealed increased expression of hematopoietic stem-cell genes and reduced expression of B-cell-lineage genes, and it was similar to the signature of BCR-ABL1-positive ALL, another high-risk subtype of ALL with a high frequency of IKZF1 deletion.

CONCLUSIONS: Genetic alteration of IKZF1 is associated with a very poor outcome in B-cell-progenitor ALL.

[Other-IDs] NLM/ NIHMS93692; NLM/ PMC2674612

65. Li ZY, Liu DP, Liang CC: New insight into the molecular mechanisms of MLL-associated leukemia.Leukemia; 2005 Feb;19(2):183-90[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] New insight into the molecular mechanisms of MLL-associated leukemia.

Rearrangements of the MLL gene (ALL1, HRX, and Hrtx) located at chromosome band 11q23 are commonly involved in adult and pediatric cases of primary acute leukemias and also found in cases of therapy-related secondary leukemias.

In our present study we review a novel cytogenetic mutation typical for childhood B-cell ALL, the intrachromosomal amplification of chromosome 21, which requires high-risk therapy irrespective of other risk factors, and which is associated with a cryptic 12;21 translocation of good prognostic value.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The prognosis for adults with precursor B-cell acutelymphoblasticleukemia (B-ALL) remains poor, in part from a lack of therapeutic targets.

We demonstrate that CRLF2 is overexpressed in approximately 15% of adult and high-risk pediatric B-ALL that lack MLL, TCF3, TEL, and BCR/ABL rearrangements, but not in B-ALL with these rearrangements or other lymphoid malignancies.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

OBJECTIVE: In childhoodacutelymphoblasticleukemia (ALL), cytogenetics plays an important role in diagnosis, allocation of treatment and prognosis.

On the basis of the conventional cytogenetic analysis, molecular methods have improved pediatric hematologists/oncologist's ability to accurately and rapidly perform risk-stratification on patients with childhood ALL during the last few years.

The aim of the present study was to assess the demography of cytogenetic abnormalities in childhood ALL.

METHOD: The study subjects consisted of 124 newly diagnosed ALL patients younger than 16 years of age, who were diagnosed at the Department of Pediatric Hematology/Oncology, Soochow University Children's Hospital.

Multiplex polymerase chain reaction (Multiplex PCR) analysis was performed to detect the 29 most common leukemia translocations for routine molecular diagnostic hematopathology practice, and complement the information gained from conventional cytogenetic analysis.

[Title]Leukemia-associated genetic aberrations in mesenchymal stem cells of children with acutelymphoblasticleukemia.

Even though childhood ALL can be cured in a large number of patients, around 20% of the patients suffer a relapse after chemotherapy.

Given the high plasticity of cells, we searched for leukemia-associated genetic aberrations and immunoglobulin (IG) gene rearrangements in mesenchymal stem cells (MSC) from childhood B-cellprecursor ALL patients.

MSC from all ten ALL patients analyzed presented the chromosomal translocations that had been detected in leukemia cells (TEL-AML1, E2A-PBX1, or MLL rearrangement).

Leukemia-specific IG gene rearrangements were detected in the MSC from three ALL patients.

The detection of leukemia-associated genetic aberrations in MSC indicates a clonal relationship between MSC and leukemia cells and suggests their involvement in the pathogenesis and/or pathophysiology of childhood ALL.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The objective of this study was to examine the incidence and characteristics of Ara-C-related fever and the frequency and severity of infections after single-drug, high-dose Ara-C treatment (HDAC) in children treated for acutelymphoblasticleukemia (ALL) or non-Hodgkin lymphoma (NHL).

Profound neutropenia and lymphopenia are causative factors for the high incidence of infections, but the risk of life-threatening complications after HDAC in children in remission of lymphoid malignancies is low, even without prophylactic use of colony-stimulating factors.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

OBJECTIVE: To study the cellular activity of asparagine synthetase in different types of childhoodacutelymphoblasticleukemia (ALL).

METHODS: The cellular activity of asparagine synthetase was detected by HPLC-FLD and Protein measurement in 28 ALL children (7 cases of T-ALL and 21 cases of B-lymphoid lineage ALL) before chemotherapy.

RESULTS: The asparagines synthetase activity levels in T-ALL children were significantly higher than those of the B-lymphoid lineage ALL patients, with the median activity level of 9.3 nM Asn/mg protein/hr vs 5.2 nM Asn/mg protein/hr (P < 0.05).

The distribution of the asparagine synthetase activity demonstrated a polymorphism in either T-ALL or B-lymphoid lineage ALL patients.

The asparagines synthetase activity levels in T-ALL are significantly higher than in B-lymphoid lineage ALL.

[Language] chi

[Publication-country] China

76. Azevedo-Silva F, Camargo Bd, Pombo-de-Oliveira MS: Implications of infectious diseases and the adrenal hypothesis for the etiology of childhood acute lymphoblastic leukemia.Braz J Med Biol Res; 2010 Mar;43(3):226-9[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Implications of infectious diseases and the adrenal hypothesis for the etiology of childhoodacutelymphoblasticleukemia.

Acute leukemia is the most frequent cancer in children.

Recently, a new hypothesis was proposed for the pathogenesis of childhoodacutelymphoblasticleukemia (ALL).

The so-called 'adrenal hypothesis' emphasized the role of endogenous cortisol in the etiology of B-cellprecursor ALL.

The adrenal hypothesis proposes that the risk of childhood B-cellprecursor ALL is reduced when early childhood infections induce qualitative and quantitative changes in the hypothalamus-pituitary-adrenal axis.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Two consecutive immunophenotypic switches in a child with MLL-rearranged acutelymphoblasticleukemia.

An 18-month-old girl was diagnosed with pre-pre-B ALL/t(4;11) leukemia, which during the treatment and after matched bone marrow transplantation (BMT), underwent two consecutive switches from lymphoid to myeloid lineage and vice versa.

The high expression of HOXA9 and FLT3 genes remaining genotypically stable in a leukemia throughout phenotypic switches, suggests that this leukemia may have originated as a common B/myeloid progenitors.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Concordance of MLL-rearranged acute leukemia in infant monozygotic twins is thought to be 100% with a very short latency period, suggesting that either the MLL fusion itself is sufficient to cause leukemia or that it promotes the rapid acquisition of additional oncogenic events that result in overt disease.

Twin A presented at age 9 months with MLL-ENL(+) acutelymphoblasticleukemia and twin B remains healthy 3 years later.

Clearance of this clone was temporally associated with viral-induced cytopenias, suggesting an immune-mediated clearance of the clone before the development of leukemia.

Thus, concordance of MLL-rearranged acute leukemia in infant monozygotic twins is not universal.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Methylenetetrahydrofolate reductase C677T polymorphism: association with risk for childhoodacutelymphoblasticleukemia and response during the initial phase of chemotherapy in greek patients.

BACKGROUND: As of late, a number of studies have focused on the association of the gene for methyletetrahydrofolate reductase (MTHFR) with risk for acutelymphoblasticleukemia (ALL) in children and in adults, as well as with response to chemotherapy.

PROCEDURE: We have analyzed the MTHFR C677T polymorphism in 52 patients and 88 control individuals, all ethnic Greek residents of northern Greece, and examined the association of this polymorphism with (a) susceptibility to childhood ALL and (b) the distribution of average plasma alanine aminotransferase (ALT) levels, white blood cell counts (WBC), and hemoglobin levels (Hb) during the induction and consolidation phases of treatment.

In addition, we observed a general tendency towards lower values in all three parameters studied, associated with the MTHFR 677CC genotype, which was more evident in the transition from the induction to the consolidation phase, indicating that MTHFR genotyping may be of prognostic value in the early phase of treatment for childhood ALL, in our population.

Based on our previous analysis of HLA-DP in childhood ALL, and evidence from in vitro studies that TEL-AML1 can activate HLA-DP-restricted T cell responses, we hypothesised that the development of TEL-AML1+ ALL might be influenced by the child's DPB1 genotype.

To test this, we analysed the frequency of six HLA-DPB1 supertypes in a population-based series of childhood leukaemias (n = 776) classified by their karyotype (TEL-AML1+, HeH and others), in comparison with newborn controls (n = 864).

[Title] Detection of early precursors of t(12;21) positive pediatric acutelymphoblasticleukemia during follow-up.

We monitored the responses of patients with pediatric acutelymphoblasticleukemia (pALL) using DNA markers, TEL/AML1 expression, and scanning fluorescence microscopy (SFM).

CD10+ ancestor cells with germline antigen receptors, but silent TEL/AML1 expression, may reside in the lymphoid stem cell compartment of treated t(12;21)-positive patients and might act as a potential source of cells for late relapses.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Clinical and cytogenetic features of pediatric dic(9;20)(p13.2;q11.2)-positive B-cellprecursoracutelymphoblastic leukemias: a Nordic series of 24 cases and review of the literature.

Although dic(9;20)(p13.2;q11.2) is a characteristic abnormality in childhood B-cellprecursoracutelymphoblastic leukemias (BCP ALL), little is known about its clinical impact or the type and frequency of additional aberrations it may occur together with.

We here review the clinical and cytogenetic features of a Nordic pediatric series of 24 patients with dic(9;20)-positive BCP ALL diagnosed 1996-2006, constituting 1.3% of the BCP ALL, as well as 47 childhood cases from the literature.

Consistent immunophenotypic features of the Nordic cases included positivity for HLA-DR, CD10, CD19, CD20, and CD22 and negativity for T-cell and myeloid markers; no detailed immunophenotypes were reported for the previously published cases.

The median patient age was 3 years, the female/male ratio was 2.0, the median white blood cell count was 24 x 10(9)/l, 11% had central nervous system involvement, and 5% had a mediastinal mass at diagnosis.

[ISSN] 1098-2264

[Journal-full-title] Genes, chromosomes & cancer

[ISO-abbreviation] Genes Chromosomes Cancer

[Language] eng

[Publication-country] United States

[Number-of-references] 38

86. Hadziselimovic F: Early successful orchidopexy does not prevent from developing azoospermia.Int Braz J Urol; 2006 Sep-Oct;32(5):570-3[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

INTRODUCTION: The incidence of Ad spermatogonia (stem cells for fertility) was assessed in 20 cryptorchid patients, all of whom had a successful orchidopexy in childhood but developed azoospermia following puberty.

The patients were classified into 2 groups according to the time of surgery: A = < 21 months of age (n = 5, mean = 10.7 +/- 8.6 months) and B = during childhood (n = 15, mean = 10.1 +/- 3 years).

We also confirmed a selective effect for B-cell acutelymphoblasticleukemia with hyperdiploidy and report a putative gender-specific effect of ARID5B SNPs on acutelymphoblasticleukemia risk in males.

This study provides a strong rationale for more detailed analysis to identify the causal variants at this locus and to better understand the overall functional contribution of ARID5B to childhoodacutelymphoblasticleukemia susceptibility.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] High hyperdiploid childhoodacutelymphoblasticleukemia.

High hyperdiploidy (51-67 chromosomes) is the most common cytogenetic abnormality pattern in childhood B-cellprecursoracutelymphoblasticleukemia (ALL), occurring in 25-30% of such cases.

Despite the high frequency of this karyotypic subgroup, many questions remain regarding the epidemiology, etiology, presence of other genetic changes, the time and cell of origin, and the formation and pathogenetic consequences of high hyperdiploidy.

However, during the last few years, several studies have addressed some of these important issues, and these, as well as previous reports on high hyperdiploid childhood ALL, are reviewed herein.